A paper claiming the danger of hydroxychloroquine with the possibility of a new corona drug is withdrawn

In the treatment of novel coronavirus infections, the authors have withdrawn a peer-reviewed paper from the medical journal Lancet, which alleged that 'taking hydroxychloroquine increases patient risk of death and heart disease.' There was a problem with the reliability of the data used for research, which caused the withdrawal of the paper.

Retraction: 'Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis'
https://www.thelancet.com/lancet/article/s0140673620313246

Covid-19 and hydroxychloroquine: a major Lancet study has been retracted-Vox
https://www.vox.com/future-perfect/2020/6/4/21280855/coronavirus-treatment-hydroxychloroquine-lancet-retraction

Authors retract influential Lancet article that found hydroxychloroquine risks-Reuters
https://www.reuters.com/article/us-health-coronavirus-hydroxychloroquine/study-authors-retract-influential-lancet-hydroxychloroquine-article-idUSKBN23B31W

A paper published in Lancet on May 22, 2020 showed that when 96,000 inpatients with a novel coronavirus infection were administered hydroxychloroquine and chloroquine phosphate , mortality and heart disease risk among inpatients were reported. Was reported to rise . This report put the World Health Organization (WHO)-led study of hydroxychloroquine on hold.

WHO suspends research on ``hydroxychloroquine'', which was expected as a new corona treatment-GIGAZINE

However, it was judged that the source and validity of the data provided by Surgisphere, a group that holds a database on hospitals operated by co-author Sapan Desai, are doubtful, so he is the co-author of the article. Three people withdrew their papers, including Mandeep Mela, a professor at Harvard Medical School. In addition, several doctors have pointed out that the relationship between the dose of hydroxychloroquine and mortality in patients has not been discovered. At the time of writing the article, Mr. Desai did not make a comment regarding the withdrawal of the paper.

Surgisphere provides data to the research team that it collected from about 96,000 patients infected with the novel coronavirus, but evidence that supports the data and specific data acquisition method is not properly shown Suspicion is on . In addition, CEO Mr. Desai has been sued for medical malpractice in the past, and the career of the employee registered as a science editor in Surgisphere is a science fiction writer, hostess, adult model. There is also a point that it lacks reliability.

A paper on novel coronaviruses and angiotensins, also based on data provided by Surgisphere, has been withdrawn from the New England Journal of Medicine as unreliable. 'We couldn't fully guarantee that the data sources were suitable for research,' said Mela, the lead author of the paper. We sincerely apologize for causing the confusion, both directly and indirectly.' I commented.

Research on hydroxychloroquine as a treatment for novel coronavirus infections has been resumed by the WHO Data Safety Monitoring Committee's 'no reason to change study' decision.

WHO resumes research on hydroxychloroquine as a new corona treatment-GIGAZINE

On the other hand, does not include the hydroxychloroquine and the active ingredient placebo in the study comparing, there is no significant difference in the hydroxychloroquine and placebo effects that have been reported, Department of Internal Medicine, Associate Professor of the University of Manitoba is one of the research team, Ryan Zalichansky argues, 'There is a strong desire for randomized clinical trials at home and abroad to provide unbiased evidence to guide the practice of novel coronavirus infections and to fight the virus.' I am.